3B BlackBio Dx concludes investor meeting with Capri Global Holdings
- 3B BlackBio Dx concluded one-on-one investor call with Capri Global Holdings
- Meeting held on September 11, 2026, from 11:00 am to 12:00 pm India Time
- Company reiterated Q1-FY27 investor presentation details during the session
- No unpublished price-sensitive information was shared with the investor

*this image is generated using AI for illustrative purposes only.
3B BlackBio Dx Limited concluded its scheduled one-on-one investor interaction with Capri Global Holdings on Friday, September 11, 2026. The virtual meeting ran from 11:00 am to 12:00 pm India Time.
The company disclosed the outcome pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management confirmed that only information available in the public domain was discussed. No unpublished price-sensitive information was shared during the session.
Meeting Details
The interaction focused on the company’s recent financial performance and strategic outlook. The company reiterated details from its Investor Presentation for Q1-FY27, which was previously intimated to stock exchanges vide Ref. No. P-66/2026-27/27 dated August 13, 2026.
| Parameter | Details |
|---|---|
| Date | September 11, 2026 |
| Time | 11:00 am to 12:00 pm India Time |
| Counterparty | Capri Global Holdings, Mumbai |
| Mode | Virtual Investor Conference Call |
| Type | One-on-One |
Presentation Material
For this meeting, the company utilized the Investor Presentation of Q1-FY27. This document was shared with investors following the declaration of financial results for the quarter ended June 30, 2026.
The disclosure was signed by Nikhil Kuber Dubey, Whole Time Director of 3B BlackBio Dx Limited (formerly Kilpest India Limited). The company noted that the date and time of such interactions are subject to change due to exigencies on the part of the investor or the company.
Historical Stock Returns for 3B BlackBio DX
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.40% | +24.91% | +18.68% | +31.38% | +31.38% | +31.38% |
How might the strategic outlook presented in the Q1-FY27 deck influence 3B BlackBio Dx's valuation multiples compared to its diagnostic peers?
What specific growth drivers or operational milestones should investors monitor in Q2-FY27 to validate the management's forward-looking statements?
Given the rebranding from Kilpest India Limited, how is the market perceiving the company's transition towards a pure-play diagnostics business?


































